You are leaving Medscape Education
Cancel Continue
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Business of Medicine
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Interprofessional
Shared Decision Making
Nurses
Pharmacists
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Friday, June 2, 2023
      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
       

      CME/CE Test

      Medscape Onsite: Prostate and Bladder Cancer Updates From the Annual American Genitourinary Meeting

      1. Which line of treatment was the IMvigor130 phase 3 study of atezolizumab plus platinum/gemcitabine vs placebo plus platinum/gemcitabine in patients with metastatic urothelial carcinoma (mUC) evaluated in?
        No prior systemic therapy in metastatic setting
        Received at least 1 prior systemic therapy in the metastatic setting
        Received at least 2 or more systemic therapies in the locally advanced setting
      2. The ARAMIS rollover study evaluated the long-term safety and tolerability of darolutamide in patients with non-metastatic castration-resistant prostate cancer? What was the main finding of this study?
        There were several new safety concerns or patients on long term treatment with darolutamide
        About 10% of patients randomized to receive darolutamide in ARAMIS remained on treatment for ≥ 4 years
        Clinical benefit and favorable safety profile of darolutamide in nmCRPC is maintained for several years in some patients
       
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.